-
1.发明申请公开(公告)号：US20130071428A1
公开(公告)日：2013-03-21
申请号：US13635384
申请日：2011-03-15
CPC classification number: C07K17/02 , A61K39/00 , A61K39/385 , A61K39/40 , A61K2039/6037 , A61K2039/627 , C07K7/08 , C07K14/33 , C07K16/1282 , A61K2300/00
Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.
Abstract translation: 本发明涉及包含至少10个氨基酸残基的肽的缀合物，其包含氨基酸序列GITELKKL，用于在施用于具有抗破伤风类毒素抗体的受试者时诱导有效的体液和细胞免疫应答。 在一个实施方案中，本发明涉及预防和治疗性疫苗，并且在进一步的实施方案中，本发明涉及癌症或感染性疾病的治疗或预防。
-
2.发明申请DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT 审中-公开将CD40激动剂递送给受试者的肿瘤排泄淋巴结节点公开(公告)号：US20110311525A1
公开(公告)日：2011-12-22
申请号：US13061366
申请日：2009-08-31
IPC: A61K39/395 , A61K31/7052 , A61P35/00 , A61K38/02
CPC classification number: A61K39/0011 , A61K9/1652 , A61K39/12 , A61K2039/505 , A61K2039/545 , A61K2039/55516 , A61K2039/585 , C07K16/2878 , C07K2317/74 , C07K2317/75 , C12N2710/20034
Abstract: The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease, wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph node of a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a CTL-activating peptide is further administered.
Abstract translation: 本发明涉及CD40激动剂用于治疗癌症，恶性前病症或感染性疾病的用途，其中CD40激动剂局部施用并靶向受试者的肿瘤引流淋巴结。 任选地，将CD40激动剂配制在缓释制剂中。 任选地，进一步施用CTL激活肽。
-
Patent Agency Ranking
3.发明授权Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens 有权免疫系统对单体黑素瘤抗原的单酚和苯二酚敏感公开(公告)号：US09393219B2
公开(公告)日：2016-07-19
申请号：US13493284
申请日：2012-06-11
Applicant: Wiete Westerhof , Cornelis Joseph Maria Melief , Rosalie Margaretha Luiten
IPC: A61K31/135 , A61K31/05 , A61K31/065
CPC classification number: A61K31/135 , A61K31/05 , A61K31/065
Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.
Abstract translation: 将某些酚类，单酚类或苯二酚代谢为反应性醌化合物，特别是邻醌和相关的反应性中间体，这是通过表现出酪氨酸酶活性的蛋白质（如人酪氨酸酶和相关蛋白质TRP1）氧化单酚和苯二酚引起的， TRP2。 该化合物起到与表达酪氨酸酶活性的蛋白质（如酪氨酸酶，TRP1和TRP2）的蛋白质的催化部位内或附近与酪氨酸酶（特别是组氨酸部分）共价结合的半抗原。 然后针对这些半抗原自身抗原进行免疫应答以治疗恶性肿瘤。
-
4.发明申请公开(公告)号：US20120315304A1
公开(公告)日：2012-12-13
申请号：US13493284
申请日：2012-06-11
Applicant: Wiete WESTERHOF , Cornelis Joseph Maria MELIEF , Rosalie Margaretha LUITEN
IPC: A61K31/05 , A61K38/21 , A61K31/085 , A61P37/04 , A61K31/185 , A61K9/00 , A61K31/4745 , A61P35/00 , A61K38/20 , A61K31/145
CPC classification number: A61K31/135 , A61K31/05 , A61K31/065
Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.
Abstract translation: 将某些酚类，单酚类或苯二酚代谢为反应性醌化合物，特别是邻醌和相关的反应性中间体，这是通过表现出酪氨酸酶活性的蛋白质（如人酪氨酸酶和相关蛋白质TRP1）氧化单酚和苯二酚引起的， TRP2。 该化合物起到与表达酪氨酸酶活性的蛋白质（如酪氨酸酶，TRP1和TRP2）的蛋白质的催化部位内或附近与酪氨酸酶（特别是组氨酸部分）共价结合的半抗原。 然后针对这些半抗原自身抗原进行免疫应答以治疗恶性肿瘤。
-
5.发明授权Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes 失效用于人T细胞应答诱导组合物的人P53蛋白的肽和人P53蛋白特异性细胞毒性T淋巴细胞
公开(公告)号：US5679641A
公开(公告)日：1997-10-21
申请号：US338634
申请日：1995-02-06
Applicant: Cornelis Joseph Maria Melief , Wybe Martin Kast
Inventor： Cornelis Joseph Maria Melief , Wybe Martin Kast
IPC: C12Q1/02 , A61K35/14 , A61K38/00 , A61K38/02 , A61K38/08 , A61K39/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07K2/00 , C07K7/06 , C07K14/435 , C07K14/47 , C12N5/06 , G01N33/53 , C07K5/00 , C12N5/00
CPC classification number: C07K14/47 , C07K14/4746 , A61K38/00
Abstract: A peptide comprising an amino acid sequence derived from human p53 protein, wherein said amino acid sequence has the ability to bind to a human MHC Class I molecule. Its use in prophylactic or therapeutic treatment of diseases such as human cancers showing p53 protein overexpression, and its use in induction of primary p53-specific T cells that can be used in therapeutic treatment. Its use in diagnostic tests or assays.
Abstract translation: PCT No.PCT / NL93 / 00102 Sec。 371日期：1995年2月6日 102（e）日期1995年2月6日PCT提交1993年5月18日PCT公布。 出版物WO93 / 24525 日期1993年12月9日一种肽，其包含衍生自人p53蛋白的氨基酸序列，其中所述氨基酸序列具有结合人MHC I类分子的能力。 其用于预防或治疗诸如显示p53蛋白过表达的人类癌症等疾病，以及其用于诱导可用于治疗性治疗的原发性p53特异性T细胞的用途。 它用于诊断测试或测定。
-
6.发明授权公开(公告)号：US09522962B2
公开(公告)日：2016-12-20
申请号：US13635384
申请日：2011-03-15
CPC classification number: C07K17/02 , A61K39/00 , A61K39/385 , A61K39/40 , A61K2039/6037 , A61K2039/627 , C07K7/08 , C07K14/33 , C07K16/1282 , A61K2300/00
Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL (residues 383-390 of SEQ ID NO: 3) for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.
Abstract translation: 本发明涉及包含至少10个氨基酸残基的肽的缀合物，其包含氨基酸序列GITELKKL（SEQ ID NO：3的残基383-390），用于在施用于具有抗体的抗体的受试者时诱导有效的体液和细胞免疫应答 破伤风类毒素。 在一个实施方案中，本发明涉及预防和治疗性疫苗，并且在进一步的实施方案中，本发明涉及癌症或感染性疾病的治疗或预防。
-
7.发明授权Peptides of human Papilloma virus for use in human T cell response inducing compositions 失效用于人T细胞应答诱导组合物的人乳头状瘤病毒的肽公开(公告)号：US07364741B1
公开(公告)日：2008-04-29
申请号：US08170344
申请日：1993-05-04
Applicant: Wybe Martin Kast , Cornelis Joseph Maria Melief , Alessandro D. Sette , John C. Sidney
CPC classification number: C07K14/005 , A61K39/00 , C12N2710/20022
Abstract: A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.
Abstract translation: 一种肽，其包含衍生自人乳头瘤病毒（HPV）蛋白质的氨基酸序列，其中所述氨基酸序列具有结合人类主要组织相容性复合物I类分子的能力。 其用于预防或治疗宫颈癌和其他HPV相关疾病。
-
-
-
-
-
-
Search Results
7
records
(took 0.012 seconds)
